Advertisement

A Simple Liquid Chromatography Tandem Mass Spectrometry Method for Quantitation of Plasma Busulfan

  • Shuang Deng
  • Michael Kiscoan
  • Clint Frazee
  • Susan Abdel-Rahman
  • Jignesh Dalal
  • Uttam GargEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1383)

Abstract

Busulfan is an alkylating agent widely used in the ablation of bone marrow cells before hematopoietic stem cell transplant. Due to large intraindividual and interindividual variations, and narrow therapeutic window, therapeutic drug monitoring of busulfan is warranted. A quick and reliable HPLC-MS/MS method was developed for the assay of plasma busulfan. HPLC involved C18 column, and MS/MS was used in electrospray ionization (ESI) positive mode. Quantitation and identification of busulfan was made using various multiple reactions monitoring (MRMs). Isotopic labeled busulfan-d8 was used as the internal standard. The method is linear from 50 to 2500 ng/mL and has with-in run and between-run imprecision of <10 %.

Key words

Busulfan Mass spectrometry Liquid chromatography Bone marrow transplant Leukemia 

References

  1. 1.
    Cavo M, Bandini G, Benni M, Gozzetti A, Ronconi S, Rosti G, Zamagni E, Lemoli RM, Bonini A, Belardinelli A et al (1998) High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant 22:27–32CrossRefPubMedGoogle Scholar
  2. 2.
    O’Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML et al (1995) Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13:2973–2979PubMedGoogle Scholar
  3. 3.
    Shah AJ, Lenarsky C, Kapoor N, Crooks GM, Kohn DB, Parkman R, Epport K, Wilson K, Weinberg K (2004) Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation. J Pediatr Hematol Oncol 26:91–97CrossRefPubMedGoogle Scholar
  4. 4.
    Slattery JT, Risler LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20:543–549CrossRefPubMedGoogle Scholar
  5. 5.
    Athanasiadou I, Angelis YS, Lyris E, Archontaki H, Georgakopoulos C, Valsami G (2014) Gas chromatographic-mass spectrometric quantitation of busulfan in human plasma for therapeutic drug monitoring: a new on-line derivatization procedure for the conversion of busulfan to 1,4-diiodobutane. J Pharm Biomed Anal 90:207–214CrossRefPubMedGoogle Scholar
  6. 6.
    Courtney JB, Harney R, Li Y, Lundell G, McMillin GA, Agarwal G, Juenke JM, Mathew A, Gonzalez-Espinoza R, Fleisher M et al (2009) Determination of busulfan in human plasma using an ELISA format. Ther Drug Monit 31:489–494CrossRefPubMedGoogle Scholar
  7. 7.
    Embree L, Burns RB, Heggie JR, Phillips GL, Reece DE, Spinelli JJ, Hartley DO, Hudon NJ, Goldie JH (1993) Gas-chromatographic analysis of busulfan for therapeutic drug monitoring. Cancer Chemother Pharmacol 32:137–142CrossRefPubMedGoogle Scholar
  8. 8.
    French D, Sujishi KK, Long-Boyle JR, Ritchie JC (2014) Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan. Ther Drug Monit 36:169–174CrossRefPubMedGoogle Scholar
  9. 9.
    Hassan M, Ehrsson H (1983) Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 277:374–380CrossRefPubMedGoogle Scholar
  10. 10.
    Juenke JM, Miller KA, McMillin GA, Johnson-Davis KL (2011) An automated method for supporting busulfan therapeutic drug monitoring. Ther Drug Monit 33:315–320CrossRefPubMedGoogle Scholar
  11. 11.
    Kellogg MD, Law T, Sakamoto M, Rifai N (2005) Tandem mass spectrometry method for the quantification of serum busulfan. Ther Drug Monit 27:625–629CrossRefPubMedGoogle Scholar
  12. 12.
    Lai WK, Pang CP, Law LK, Wong R, Li CK, Yuen PM (1998) Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem 44:2506–2510PubMedGoogle Scholar
  13. 13.
    Moon SY, Lim MK, Hong S, Jeon Y, Han M, Song SH, Lim KS, Yu KS, Jang IJ, Lee JW et al (2014) Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry. Ann Lab Med 34:7–14PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Murdter TE, Coller J, Claviez A, Schonberger F, Hofmann U, Dreger P, Schwab M (2001) Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin Chem 47:1437–1442PubMedGoogle Scholar
  15. 15.
    Quernin MH, Duval M, Litalien C, Vilmer E, Aigrain EJ (2001) Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children. J Chromatogr B Biomed Sci Appl 763:61–69CrossRefPubMedGoogle Scholar
  16. 16.
    Vassal G, Re M, Gouyette A (1988) Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 428:357–361CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Shuang Deng
    • 1
    • 2
  • Michael Kiscoan
    • 1
  • Clint Frazee
    • 1
  • Susan Abdel-Rahman
    • 2
  • Jignesh Dalal
    • 2
  • Uttam Garg
    • 1
    Email author
  1. 1.Department of Pathology and Laboratory MedicineChildren’s Mercy Hospitals and ClinicsKansas CityUSA
  2. 2.Department of PediatricsChildren’s Mercy Hospitals and ClinicsKansas CityUSA

Personalised recommendations